For patients undergoing surgery for elbow trauma, treatment with the hemostatic drug tranexamic acid (TXA) is associated with a decreased incidence of heterotopic ossification (HO) – a common complication of abnormal bone formation, reports a study in The Journal of Bone & Joint Surgery.
Trailing Novartis and Eli Lilly, radiopharmaceuticals startup Full-Life Technologies nabs $63M to test new PSMA drug
As the US radiopharmaceutical space heats up with the acquisitions of RayzeBio and Point Biopharma, a younger startup based out of China and Belgium has